Cargando…

卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250959/
https://www.ncbi.nlm.nih.gov/pubmed/35680603
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.05.015
_version_ 1784739926925901824
collection PubMed
description
format Online
Article
Text
id pubmed-9250959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-92509592022-07-08 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性 Zhonghua Xue Ye Xue Za Zhi 经验交流 Editorial office of Chinese Journal of Hematology 2022-05 /pmc/articles/PMC9250959/ /pubmed/35680603 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.05.015 Text en 2022年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 经验交流
卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
title 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
title_full 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
title_fullStr 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
title_full_unstemmed 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
title_short 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
title_sort 卡瑞利珠单抗联合avd方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
topic 经验交流
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250959/
https://www.ncbi.nlm.nih.gov/pubmed/35680603
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.05.015
work_keys_str_mv AT kǎruìlìzhūdānkàngliánhéavdfāngànyīxiànzhìliáojīngdiǎnxínghuòqíjīnlínbāliúdeyǒuxiàoxìnghéānquánxìng
AT kǎruìlìzhūdānkàngliánhéavdfāngànyīxiànzhìliáojīngdiǎnxínghuòqíjīnlínbāliúdeyǒuxiàoxìnghéānquánxìng
AT kǎruìlìzhūdānkàngliánhéavdfāngànyīxiànzhìliáojīngdiǎnxínghuòqíjīnlínbāliúdeyǒuxiàoxìnghéānquánxìng
AT kǎruìlìzhūdānkàngliánhéavdfāngànyīxiànzhìliáojīngdiǎnxínghuòqíjīnlínbāliúdeyǒuxiàoxìnghéānquánxìng
AT kǎruìlìzhūdānkàngliánhéavdfāngànyīxiànzhìliáojīngdiǎnxínghuòqíjīnlínbāliúdeyǒuxiàoxìnghéānquánxìng
AT kǎruìlìzhūdānkàngliánhéavdfāngànyīxiànzhìliáojīngdiǎnxínghuòqíjīnlínbāliúdeyǒuxiàoxìnghéānquánxìng